Immunization with the MipA, Skp, or ETEC_2479 Antigens Confers Protection against Enterotoxigenic E. coli Strains Expressing Different Colonization Factors in a Mouse Pulmonary Challenge Model by Michael P. Hays et al.
ORIGINAL RESEARCH
published: 12 December 2016
doi: 10.3389/fcimb.2016.00181
Frontiers in Cellular and Infection Microbiology | www.frontiersin.org 1 December 2016 | Volume 6 | Article 181
Edited by:
Alfredo G. Torres,
University of Texas Medical Branch,
USA
Reviewed by:
Subhra Chakraborty,
Johns Hopkins University, USA
Roberto Mauricio Vidal,
University of Chile, Chile
Mark S. Riddle,
Naval Medical Research Center, USA
*Correspondence:
Philip R. Hardwidge
hardwidg@vet.k-state.edu
†
Present Address:
Amit Kumar,
Department of Pathobiology and
Diagnostic Investigation, Michigan
State University, Lansing, MI, USA
Received: 22 September 2016
Accepted: 28 November 2016
Published: 12 December 2016
Citation:
Hays MP, Kumar A,
Martinez-Becerra FJ and
Hardwidge PR (2016) Immunization
with the MipA, Skp, or ETEC_2479
Antigens Confers Protection against
Enterotoxigenic E. coli Strains
Expressing Different Colonization
Factors in a Mouse Pulmonary
Challenge Model.
Front. Cell. Infect. Microbiol. 6:181.
doi: 10.3389/fcimb.2016.00181
Immunization with the MipA, Skp, or
ETEC_2479 Antigens Confers
Protection against Enterotoxigenic
E. coli Strains Expressing Different
Colonization Factors in a Mouse
Pulmonary Challenge Model
Michael P. Hays 1, Amit Kumar 1 †, Francisco J. Martinez-Becerra 2 and
Philip R. Hardwidge 1*
1College of Veterinary Medicine, Kansas State University, Manhattan, KS, USA, 2 Immunology Core Laboratory of the Kansas
Vaccine Institute and Department of Pharmaceutical Chemistry, University of Kansas, Lawrence, KS, USA
Achieving cross-protective efficacy against multiple bacterial strains or serotypes is an
important goal of vaccine design. Enterotoxigenic Escherichia coli (ETEC) is an important
cause of diarrheal disease in underdeveloped nations. We have been interested in
identifying and characterizing ETEC antigens that generate protective immune responses
independent of ETEC colonization factor (CF) expression. Our previous studies used
proteomics to identify the ETEC MipA, Skp, and ETEC_2479 proteins as effective in
protecting mice from homologous challenge with ETEC H10407 using a pulmonary
inoculation model. This model permits analysis of mouse survival, bacterial clearance,
and the production of secretory IgA (sIgA) and has been employed previously for studies
of enteric pathogens for which robust oral challenge models do not exist. MipA belongs
to a family of proteins involved in remodeling peptidoglycan. Skp rescues misdirected
outer membrane proteins. ETEC_2479 is predicted to function as an outer membrane
porin. These proteins are conserved in pathogenic ETEC strains as well as in commensal
Proteobacteria. Antibodies produced against the ETEC MipA, Skp, and ETEC_2479
proteins also reduced the adherence of multiple ETEC strains differing in CF type to
intestinal epithelial cells. Here we characterized the ability of 10 heterologous ETEC
strains that differ in CF type to cause clinical signs of illness in mice after pulmonary
challenge. ETEC strains C350C1A, E24377A, E7476A, WS2173A, and PE360 caused
variable degrees of lethality in this mouse model, while ETEC strains B7A, WS6866B,
2230, ARG-2, and 8786 did not. Subsequent challenge experiments in which mice were
first vaccinated intranasally with MipA, Skp, or ETEC_2479, when combined with cholera
toxin, showed both that each antigen was protective and that protection was strongly
correlated with fecal IgA concentrations. We conclude that the MipA, Skp, or ETEC_2479
antigens generate protection in the mouse pulmonary challenge model against ETEC
strains that express different CFs.
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INTRODUCTION
Enterotoxigenic Escherichia coli (ETEC) continues to be a health
scourge both to endemic populations living in underdeveloped
countries, especially children, as well as to vacationers and
military personnel that travel to these regions (Fleckenstein et al.,
2010). We have been interested in identifying and characterizing
ETEC proteins that might serve as potential vaccine targets
(Kumar et al., 2015; Hays et al., 2016). Many previous vaccine
strategies have focused on heterogeneous surface structures
known as colonization factors (CFs; Fleckenstein et al., 2014).
However, given the diversity of CFs, identification of additional
antigens may improve the cross-protective efficacy of future
vaccine formulations.
We have been characterizing the potential protective efficacy
of the ETECMipA, Skp, and ETEC_2479 proteins in a pulmonary
challenge model (Kumar et al., 2015). We focused on these
antigens after performing proteomic studies of ETEC H10407
(Kumar et al., 2015). MipA belongs to a family of proteins
involved in remodeling peptidoglycan. Skp rescues misdirected
outer membrane proteins. ETEC_2479 is predicted to function
as an outer membrane porin (Kumar et al., 2015). While the
potential role of these proteins in ETEC virulence is not apparent,
it is known that these proteins are conserved among pathogenic
and non-pathogenic E. coli (Kumar et al., 2015; Hays et al., 2016).
It is also known that MipA can be detected in immunoblots using
sera from mice and humans (Roy et al., 2010).
The pulmonary challenge model permits analysis of mouse
survival, bacterial clearance, and the production of secretory
IgA (sIgA) (van de Verg et al., 1995; Turbyfill et al., 2000) and
has been employed previously for studies of enteric pathogens
for which robust oral challenge models do not exist including
the analysis of pathogenicity and immune responses to several
ETEC strains (Byrd and Cassels, 2003). We found previously
that immunizing mice with MipA, Skp, and ETEC_2479 was
protective against homologous challenge with ETEC H1407
(Kumar et al., 2015). Furthermore, despite the conservation of
these antigens among Gram-negative bacteria, mouse health was
not negatively impacted nor were significant alterations to the
mouse intestinalmicrobiota observed as a function of vaccination
TABLE 1 | ETEC strains used in this study.
Strain CF type Toxin(s) Serotype Location Reference MipA Skp ETEC_2749
H10407 CFA/I LT, STh-STp O78:H11 Bangladesh Evans and Evans, 1973 + + +
E24377A CS1, CS3 LT, ST O139:H28 Egypt Tacket et al., 1994 + + +
B7A CS6 LT, ST O148:H28 Vietnam DuPont et al., 1971 + + +
WS6866B CS8 LT O25:H- Egypt Shaheen et al., 2004 + + +
2230 CS10 LT, STp 025:H16 Senegal Darfeuille-Michaud et al., 1986 + + +
350C1A CS12 LT, STp O159:H4 Kenya Levine et al., 1983 + + +
PE360 CS13 LT O9:H- Australia Heuzenroeder et al., 1990 + + +
E7476A CS14 STh O166:H27 South Africa McConnell et al., 1989 + + +
8786 CS15 – O117:H4 Burundi S. Savarino + + +
ARG-2 CS18 LT, STp O20:K27:H- Argentina Viboud et al., 1993 + + +
WS2173A CS23 LT O71:H4 Egypt S. Savarino + + +
(Hays et al., 2016). Antibodies raised against the MipA, Skp, and
ETEC_2479 antigens also reduced the in vitro cell adherence of
a panel of heterologous ETEC strains (Kumar et al., 2015). Here
we determined the extent to which vaccination with MipA, Skp,
or ETEC_2479 would protect mice challenged intranasally with a
panel of diverse ETEC strains differing in CF type.
MATERIALS AND METHODS
Ethics Statement
The Kansas State University Institutional Animal Care and Use
Committee approved the animal procedures (IACUC protocol
#3196) in the context of the Kansas State University Animal
Welfare Assurance Number A3609-01, in compliance with the
Public Health Service (PHS) Policy on Humane Care and Use of
Laboratory Animals.
Bacterial Strains and Infections
The ETEC strains used are described in Table 1. Female
BALB/c mice (3 weeks old) were obtained from the Jackson
Laboratory (Bar Harbor, Maine), housed in microisolator cages,
and provided with food and water ad libitum.
We first determined the ability of 10 ETEC strains other
than H10407 to induce clinical signs of illness in a pulmonary
challenge model. ETEC strains were cultivated overnight on
CFA agar plates, resuspended in sterile phosphate-buffered saline
(PBS) and diluted to an OD600 of 1.0 [∼1 ∗ 10 colony forming
units (CFUs)/ml; (Byrd and Cassels, 2003)]. Mice were lightly
anesthetized with isoflurane and challenged intranasally with 5 ∗
108 CFUs of individual ETEC strains by dropwise administration
of 50 µl of the ETEC suspensions to the external nares of each
mouse. Mice were observed every 4 h after challenge and clinical
signs of illness (lack of responsiveness to stimulation, hunched
posture, ruﬄed hair coat, dehydration) were recorded. If mice
displayed clinical signs of illness, or at the end of the study (7 d),
they were euthanized, necropsied, and their lungs were removed
aseptically. Lungs were homogenized, serially diluted in PBS, and
plated on MacConkey agar to enumerate ETEC.
For vaccination studies, antigens were administered
intranasally at 20 µg/dose with 2.5 µg of cholera toxin
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(Sigma-Aldrich) in 25 µl PBS to the external nares of mice that
had been lightly anesthetized with isoflurane. Booster doses were
administered 2- and 4-weeks after the initial vaccination. Mice
were then challenged with ETEC strains as described above.
The antigens used in this study were purified and prepared as
glutathione-S-transferase (GST)-fusion proteins as described
previously (Kumar et al., 2015; Hays et al., 2016). A GST
epitope control protein was also used as a negative control for
immunization studies.
Immunoassays
IgA concentrations in mouse feces were quantified using ELISAs.
Five fresh stool pellets from each animal were added to 1 ml
of fecal reconstitution buffer (50 mM ethylenediaminetetraacetic
acid (EDTA), 0.1 mg/ml soybean trypsin inhibitor, 1.39
µg/ml phenylmethylsulfonylfluoride (PMSF), and homogenized.
Samples were centrifuged (5 min, 5000 g) and supernatants
(50 µl) were added to polystyrene 96-well, flat bottom plates
(Whatman) that had coated with 0.5 µg/ml of each purified
protein or BSA. After overnight incubation, a rabbit anti-mouse
IgA HRP detection antibody (Sigma) diluted 1:4000 in 0.1%
PBS-Tween was added. Plates were developed with 1-StepTM
Ultra TMB-ELISA (Thermo) and quenched with 3 N H2SO4.
Absorbance was read at 450 nm.
Statistical Analyses
Differences in mouse survival as a function of time after ETEC
challenge were analyzed using Log-rank tests. Differences in both
ETEC loads in mouse lungs and in fecal IgA concentrations were
analyzed using Kruskal-Wallis tests. Asterisks indicate significant
differences at p < 0.05.
RESULTS
We previously reported the efficacy of immunizing mice with
recombinant forms of the ETEC H10407 Skp, MipA, and
ETEC_2479 proteins in protecting mice against an otherwise
lethal challenge with ETEC H10407 (Kumar et al., 2015). We
had also shown previously that antibodies raised against the Skp,
MipA, and ETEC_2479 proteins were able to protect cultured
intestinal epithelial cells from adherence by these ETEC strains
(Kumar et al., 2015). Here we desired to determine the extent
to which immunizing mice with these antigens might confer
protection toward heterologous ETEC strains that differ in CF
type.
We infected 11 separate groups of mice (n = 5 group) with
10 different ETEC strains (5 ∗ 108 CFUs), as well as with
ETEC H10407 as a positive control, and evaluated the extent to
which they induced clinical signs of illness in the mice meriting
euthanasia. These strains were chosen for their diversities in CF
type, geographical points of isolation, and toxins (Table 1).
We observed that, in addition to H10407 (27/29 mice),
C350C1A (14/15 mice) caused extensive amounts of lethality,
with median survival times of 36 h (Figure 1A). E24377A,
E7476A, WS2173A, and PE360 yielded intermediate phenotypes,
causing lethality in 13/15, 10/13, 8/15, and 7/13 mice,
respectively, with median survival times of 44, 44, 40, and 40 h
FIGURE 1 | ETEC strains that cause illness in the mouse pulmonary
challenge model. (A) Mouse survival is plotted as a function of time (h) after
mice were inoculated with the indicated ETEC strains. H10407, n = 29;
350C1A and E24377A, n = 15; E7476A, WS2173A, and PE360 n =13; B7A,
WS6866B, 2230, ARG-2, and 8786, n = 5/group. Asterisks indicate
significantly different (p < 0.05) mouse survival, log-rank test. (B) ETEC loads
(CFUs/g lung) in mice infected with the indicated ETEC strains at time of
euthanasia or at the end of the study (7 d), n = 5/group. Asterisks indicate
significantly different (p < 0.05) ETEC loads in mouse lungs, Kruskal-Wallis
test.
(Figure 1A). ETEC strains B7A, WS6866B, 2230, ARG-2, and
8786 caused no lethality (0/5 mice).
We also quantified the amounts of ETEC strains present in the
mouse lungs at the time of euthanasia. ETEC loads were relatively
high in mouse lungs in which infection caused lethality, while
they were relatively low in mouse lungs in which infections were
non-lethal (Figure 1B; p< 0.05, Kruskal-Wallis test). Given these
data, we therefore pursued vaccination studies with the strains
PE360, WS2173A, E7476A, E24377A, and C350C1A.
Mice were immunized three times at 2-week intervals with
individual antigens combined with cholera toxin. Mice were
then inoculated intranasally with individual ETEC strains and
evaluated for clinical signs of disease over a 7-day period. All
three antigens were protective against the infectious challenge,
regardless of the ETEC strain (Figure 2A). Whereas mice
vaccinated with either PBS or a GST-epitope control protein
succumbed to infection at similar rates and frequencies as shown
in initial studies (Figure 1A), mice vaccinated with either Skp,
MipA, or ETEC_2479 were generally protected from ETEC
challenge, with only 1 or 2/10 non-respondingmice in each group
(Figure 2A, Table 2; p < 0.05, Log-rank test).
We observed high loads of ETEC (∼106−10 CFUs/g) in the
lungs of mice that were euthanized due to their presentation of
clinical signs of disease (Figure 2B). By contrast, relatively little
ETEC was cultured from the lungs of mice that survived the
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FIGURE 2 | Impact of vaccination on mouse survival after pulmonary challenge with ETEC. (A) Mouse survival is plotted as a function of time (h) after mice
were inoculated with the indicated ETEC strains following intranasal immunization with the indicated antigens, n = 10–15. Asterisks indicate significantly different
(p < 0.05) mouse survival, log-rank test. (B) ETEC loads (CFUs/g lung) in mice infected with the indicated ETEC strains at time of euthanasia or at the end of the study
(7 d). Open symbols indicate mice that survived for the duration of the study. Closed symbols indicate mice that were euthanized due to their display of clinical
signs of illness, n = 10–15. Asterisks indicate significantly different (p < 0.05) ETEC loads in mouse lungs, Kruskal-Wallis test. (C) Fold change in mouse fecal IgA
concentrations after immunization with the indicated antigens. Open symbols indicate mice that survived for the duration of the study. Closed symbols indicate mice
that were euthanized due to their display of clinical signs of illness. n = 10. Asterisks indicate significantly different (p < 0.05) fecal IgA concentrations, Kruskal-Wallis
test.
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TABLE 2 | Pulmonary challenge data.
Strain Median Survival rate
survival (h)a
(# survived/# challenged) after challenge in
vaccinated mice
PBS GST Skp MipA 2479
H10407 36 2/29b 2/20b 17/25b 16/25b 22/25b
350C1A 36 3/15 1/10 9/10 8/10 9/10
PE360 40 6/13 5/10 10/10 8/10 10/10
WS2173A 40 5/13 4/10 9/10 9/10 10/10
E7476A 44 2/13 2/10 10/10 9/10 9/10
E24377A 44 2/15 2/10 9/10 9/10 10/10
aNo lethality was observed for ETEC B7A, WS6866B, 2230, 8786, and ARG-2 when
administered at a dose of 5 * 10
8 CFUs, so these strains were not used in vaccination
studies.
bData were previously described in Kumar et al. (2015).
infection (Figure 2B). ETEC loads were inversely related to fecal
IgA concentrations in mice (Figure 2C). Fecal IgA responses
were significantly correlated withmouse survival, asmice that did
not develop significant fecal IgA responses against the antigens
did not survive the infectious challenge (Figure 2C). The results
described here support our previous findings that characterized
the ability of antisera raised against Skp, MipA, or ETEC_2479
to protect against the adherence of the strains described here to
intestinal epithelial cells (Kumar et al., 2015).
DISCUSSION
We have established here that immunizing mice with the Skp,
MipA, or ETEC_2479 antigens protects mice not only against
challenge with ETEC H10407, but also against challenge with
the ETEC strains PE360, WS2173A, E7476A, E24377A, and
C350C1A. The ability of different ETEC strains to cause disease
in mice using the pulmonary challenge model appeared to be
unrelated to toxin type, as strains encoding LT and/or ST were
equally distributed among strains that did or did not cause
disease. It is unclear why some strains cause illness in this model
and others do not. This topic could be addressed in the future
by conducting comparative genome analyses to identify virulence
determinants.
While Byrd et al. previously observed that challenge of BALB/c
mice with 5 ∗ 108 CFUs of ETEC B7A caused mortality in
25% (3/12) mice (Byrd and Cassels, 2003), we did not observe
any mortality at this dose. A limitation of our study is that we
conducted all challenge assays using a single dose (for direct
comparison to our previous studies of ETEC H10407), rather
than performing dose-finding assays. It is conceivable that higher
doses of B7A, WS6866B, 2230, ARG-2, and 8786 could cause
mouse mortality in this challenge model. The ability of some
ETEC strains to colonize mice in this model may also be related
to their different CF types.
While the pulmonary challenge model is useful in the
preliminary assessment of vaccine antigens in the study of
enteric pathogens for which robust oral challenge models do
not exist (Byrd and Cassels, 2003), there are several significant
limitations to this model. These limitations include the lack of
diarrhea, potential differences in ETEC receptors between lung
and intestinal tissue, and differing microbiomes and mucosal
interfaces. Our use of CT as an adjuvant for vaccination also
limits the potential clinical relevance of our data.
As expected, surviving animals consistently had lower CFU
counts in the lungs. Differences in IgA responses among mice
matched the protection patterns across vaccinated animals. These
data suggest that mucosal immunity, and in particular, levels
of specific IgA might play a role in protection. Opsonization
and/or direct anti-microbial activity might also play a role
during infection (Eyles et al., 1998). Further studies will define
the particular role of IgA in this model. We did not observe
significant differences in cytokine responses when we analyzed
lung homogenates using a mouse TH1/TH2 9-Plex Tissue
Culture Kit (Meso Scale Discovery; data not shown). We plan
in subsequent experiments to evaluate the extent to which these
antigens may have cross-protective efficacy if used with adjuvants
other than cholera toxin and/or in other routes of administration.
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